CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Fiche du document
2013
- doi: 10.1007/s00262-012-1381-7
- issn: 0340-7004
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1007/s00262-012-1381-7
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/23242316
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1432-0851
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_ED058D025B507
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
MeltingCiter ce document
S. Corgnac et al., « CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. », Serveur académique Lausannois, ID : 10.1007/s00262-012-1381-7
Métriques
Partage / Export
Résumé
Despite the well-established antitumor activity of CD1d-restricted invariant natural killer T lymphocytes (iNKT), their use for cancer therapy has remained challenging. This appears to be due to their strong but short-lived activation followed by long-term anergy after a single administration of the CD1d agonist ligand alpha-galactosylceramide (αGC). As a promising alternative, we obtained sustained mouse iNKT cell responses associated with prolonged antitumor effects through repeated administrations of tumor-targeted recombinant sCD1d-antitumor scFv fusion proteins loaded with αGC. Here, we demonstrate that CD1d fusion proteins bound to tumor cells via the antibody fragment specific for a tumor-associated antigen, efficiently activate human iNKT cell lines leading to potent tumor cell lysis. The importance of CD1d tumor targeting was confirmed in tumor-bearing mice in which only the specific tumor-targeted CD1d fusion protein resulted in tumor inhibition of well-established aggressive tumor grafts. The therapeutic efficacy correlated with the repeated activation of iNKT and natural killer cells marked by their release of TH1 cytokines, despite the up-regulation of the co-inhibitory receptor PD-1. Our results demonstrate the superiority of providing the superagonist αGC loaded on recombinant CD1d proteins and support the use of αGC/sCD1d-antitumor fusion proteins to secure a sustained human and mouse iNKT cell activation, while targeting their cytotoxic activity and cytokine release to the tumor site.